- Home
- BLRX vs CLRB Comparison
BLRX vs CLRB Comparison
Compare BLRX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CLRB
- Stock Information
- Founded
- BLRX 2003
- CLRB 2002
- Country
- BLRX Israel
- CLRB United States
- Employees
- BLRX N/A
- CLRB N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- CLRB Health Care
- Exchange
- BLRX Nasdaq
- CLRB Nasdaq
- Market Cap
- BLRX 12.1M
- CLRB 12.5M
- IPO Year
- BLRX 2011
- CLRB N/A
- Fundamental
- Price
- BLRX $5.74
- CLRB $0.36
- Analyst Decision
- BLRX Strong Buy
- CLRB Hold
- Analyst Count
- BLRX 2
- CLRB 2
- Target Price
- BLRX $19.00
- CLRB N/A
- AVG Volume (30 Days)
- BLRX 2.0M
- CLRB 34.3M
- Earning Date
- BLRX 05-27-2025
- CLRB 05-13-2025
- Dividend Yield
- BLRX N/A
- CLRB N/A
- EPS Growth
- BLRX N/A
- CLRB N/A
- EPS
- BLRX N/A
- CLRB N/A
- Revenue
- BLRX $22,340,000.00
- CLRB N/A
- Revenue This Year
- BLRX N/A
- CLRB N/A
- Revenue Next Year
- BLRX N/A
- CLRB N/A
- P/E Ratio
- BLRX N/A
- CLRB N/A
- Revenue Growth
- BLRX 91.68
- CLRB N/A
- 52 Week Low
- BLRX $2.30
- CLRB $0.22
- 52 Week High
- BLRX $35.60
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- BLRX 73.10
- CLRB 61.13
- Support Level
- BLRX $3.88
- CLRB $0.23
- Resistance Level
- BLRX $7.77
- CLRB $0.69
- Average True Range (ATR)
- BLRX 0.75
- CLRB 0.05
- MACD
- BLRX 0.19
- CLRB 0.02
- Stochastic Oscillator
- BLRX 56.81
- CLRB 26.84
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.